Literature DB >> 26948652

Prognostic value of metabolic tumour volume and total lesion glycolysis in 18F-FDG PET/CT scans in locally advanced breast cancer staging.

A Jiménez-Ballvé1, M García García-Esquinas2, O Salsidua-Arroyo2, A Serrano-Palacio2, J A García-Sáenz3, A Ortega Candil2, M E Fuentes Ferrer4, C Rodríguez Rey2, J M Román-Santamaría5, F Moreno3, J L Carreras-Delgado2.   

Abstract

OBJECTIVE: To determine whether metabolic tumour volume (MTV) and total lesion glycolysis (TLG) are able to predict recurrence risk in locally advanced breast cancer (LABC) patients.
MATERIAL AND METHODS: Retrospective study of LABC patients who undertook neoadjuvant, local and adjuvant treatment and follow up. A 18F-FDG PET/CT study for initial staging was performed analysing in this study different metabolic parameters (MTV, TLG, SUVmax and SUVmed) both in the primary tumour (T) as well as in axillary nodes (N) and whole-body (WB).
RESULTS: Forty females were included between January 2010-2011; follow up until January 2015 was completed. The average follow-up was 46 months. Twenty percent presented recurrence: local disease (n=2) and distant metastasis (n=6); 3 patients died (38% of the patients which recurred and 7.5% from the total). SUVmax, MTV and TLG, in T, N and WB, were higher in those patients with recurrence. The MTV and TLG parameters in the tumour (T) were related to the recurrence rate (P=.020 and P=.028, respectively); whereas SUVmax in the lymph nodes (N) was significantly related (P=.008) to the recurrence rate. The best cut-off points to predict recurrence where: MTV T ≥19.3cm3, TLG T≥74.4g and SUVmax N≥13.8, being 10-12 times more likely to recidivate when these thresholds where exceeded. Tumour grade was the only clinical-pathological variable which was related to recurrence probability (p=.035).
CONCLUSIONS: In this study of LABC patients the metabolic parameters which have a better relationship with recurrence rate are: MTV and TLG in the primary tumour, SUVmax in the regional lymph node disease and whole-body PET data.
Copyright © 2016 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

Entities:  

Keywords:  (18)F-FDG; Carcinoma localmente avanzado de mama; Glucólisis tumoral total; Locally advanced breast cancer; Metabolic tumour volume; PET/CT; PET/TC; Total lesion glycolysis; Volumen metabólico tumoral

Mesh:

Substances:

Year:  2016        PMID: 26948652     DOI: 10.1016/j.remn.2016.01.007

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  4 in total

1.  The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer.

Authors:  Y-H Qu; N Long; C Ran; J Sun
Journal:  Clin Transl Oncol       Date:  2020-07-18       Impact factor: 3.405

2.  Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.

Authors:  Yi Li; Cheng Liu; Bibo Wang; Xichun Hu; Chengcheng Gong; Yannan Zhao; Yizhao Xie; Yingjian Zhang; Shaoli Song; Zhongyi Yang; Biyun Wang
Journal:  Int J Gen Med       Date:  2021-05-11

3.  Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [18F]FDG PET/CT in Early Triple-Negative Breast Cancer.

Authors:  Clément Bouron; Clara Mathie; Valérie Seegers; Olivier Morel; Pascal Jézéquel; Hamza Lasla; Camille Guillerminet; Sylvie Girault; Marie Lacombe; Avigaelle Sher; Franck Lacoeuille; Anne Patsouris; Aude Testard
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

4.  Investigation of Added Value of Imaging Performed in a Prone Position to Standard 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Staging in Patients with Breast Cancer.

Authors:  Ezgi Başak Erdoğan; Mehmet Aydın
Journal:  Mol Imaging Radionucl Ther       Date:  2022-02-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.